Tirzepatide Titration and Dosing

Initial Dosing and Escalation Protocol

The American Diabetes Association recommends starting with 2.5 mg of tirzepatide subcutaneously once weekly for the first 4 weeks, then increasing by 2.5 mg every 4 weeks until the target maintenance dose is reached 1, 2
For patients targeting the 10 mg dose, the recommended escalation protocol is to increase to 7.5 mg once weekly for weeks 9-12, and then to 10 mg once weekly for week 13 and beyond 1, 2
For patients targeting the 15 mg dose, the recommended escalation protocol is to increase to 7.5 mg once weekly for weeks 9-12, then to 10 mg once weekly for weeks 13-16, then to 12.5 mg once weekly for weeks 17-20, and finally to 15 mg once weekly for week 21 and beyond 1, 2

The maximum recommended maintenance dose of 15 mg once weekly provides the greatest weight loss benefit, with a 14.7% reduction from baseline 1, 3
The 10 mg dose provides substantial efficacy, with a 12.8% weight reduction, and may be appropriate for patients who cannot tolerate the 15 mg dose 1
The 5 mg dose is the minimum effective maintenance dose, with a 10% weight reduction 1, 4

For patients with renal impairment, caution should be used when initiating or increasing the dose of tirzepatide due to the potential risk of acute kidney injury 1, 2
Patients using oral contraceptives should be advised to switch to a non-oral method or add a non-oral method for 4 weeks after initiation and for 4 weeks after each dose escalation 1
Oral medications with narrow therapeutic indices, such as warfarin, should be monitored closely during tirzepatide therapy 1, 2

Tirzepatide demonstrates superior weight loss compared to GLP-1 receptor agonists like semaglutide and liraglutide 3

Patients should be monitored for signs of pancreatitis, although causality has not been established 2
Potential gallbladder-related complications should be watched for during tirzepatide therapy 1, 2
Severe gastrointestinal disorders, including constipation and small bowel obstruction/ileus progression, should be monitored closely during tirzepatide therapy 1, 2